Ionis Pharmaceuticals IONS Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Ionis Pharmaceuticals (IONS) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $2.73M in Q1 2026.
- How has Ionis Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Ionis Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 58.3% year-over-year, from $1.73M to $2.73M.
- What is the long-term trend for Ionis Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -51.1% compound annual growth rate (CAGR), from $4.31M to $246K.